DRRX Durect Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: DRRX

Price (delayed)

$0.62

Market cap

$18.49M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.52

Enterprise value

$2.66M

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic ...

Highlights
Durect's equity has soared by 162% from the previous quarter but it has plunged by 59% YoY
The company's quick ratio has shrunk by 74% YoY but it rose by 24% QoQ
Durect's gross profit has shrunk by 64% YoY and by 57% QoQ
The revenue has dropped by 60% year-on-year and by 53% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.durect.com/
Peers: JNJ PCRX PFE HRTX

Key stats

What are the main financial stats of DRRX
Market
Shares outstanding
29.83M
Market cap
$18.49M
Enterprise value
$2.66M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.19
Price to sales (P/S)
1.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.29
Earnings
Revenue
$9.19M
EBIT
-$33.82M
EBITDA
-$33.66M
Free cash flow
-$34.57M
Per share
EPS
-$1.52
Free cash flow per share
-$1.27
Book value per share
$0.52
Revenue per share
$0.34
TBVPS
$1.78
Balance sheet
Total assets
$54.73M
Total liabilities
$40.32M
Debt
$23.15M
Equity
$14.41M
Working capital
$7.03M
Liquidity
Debt to equity
1.61
Current ratio
1.19
Quick ratio
1.08
Net debt/EBITDA
0.47
Margins
EBITDA margin
-366.1%
Gross margin
82.9%
Net margin
-398.7%
Operating margin
-458.2%
Efficiency
Return on assets
-66.1%
Return on equity
-243.4%
Return on invested capital
N/A
Return on capital employed
-188.2%
Return on sales
-367.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DRRX stock price

How has the Durect stock price performed over time
Intraday
-4.62%
1 week
-4.62%
1 month
-75.1%
1 year
-85.23%
YTD
-82.08%
QTD
-75.1%

Financial performance

How have Durect's revenue and profit performed over time
Revenue
$9.19M
Gross profit
$7.62M
Operating income
-$42.13M
Net income
-$36.65M
Gross margin
82.9%
Net margin
-398.7%
The net margin has dropped by 191% year-on-year and by 114% since the previous quarter
DRRX's operating margin has shrunk by 157% QoQ
Durect's gross profit has shrunk by 64% YoY and by 57% QoQ
The revenue has dropped by 60% year-on-year and by 53% since the previous quarter

Growth

What is Durect's growth rate over time

Valuation

What is Durect stock price valuation
P/E
N/A
P/B
1.19
P/S
1.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.29
The EPS is down by 8% year-on-year
Durect's equity has soared by 162% from the previous quarter but it has plunged by 59% YoY
DRRX's P/B is 87% below its last 4 quarters average of 9.3 and 87% below its 5-year quarterly average of 9.2
The price to sales (P/S) is 86% lower than the 5-year quarterly average of 13.3 and 68% lower than the last 4 quarters average of 5.8
The revenue has dropped by 60% year-on-year and by 53% since the previous quarter

Efficiency

How efficient is Durect business performance
The ROS has dropped by 189% year-on-year and by 114% since the previous quarter
Durect's ROA has plunged by 61% YoY and by 8% from the previous quarter
Durect's ROE has decreased by 36% from the previous quarter

Dividends

What is DRRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DRRX.

Financial health

How did Durect financials performed over time
The total assets is 36% more than the total liabilities
The company's quick ratio has shrunk by 74% YoY but it rose by 24% QoQ
DRRX's current ratio has dropped by 73% year-on-year but it is up by 23% since the previous quarter
The debt is 61% greater than the equity
Durect's equity has soared by 162% from the previous quarter but it has plunged by 59% YoY
The debt to equity has soared by 137% year-on-year but it has dropped by 61% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.